Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Micro Therapeutics, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Micro Therapeutics, Inc.: Newly formed Genyx Medical subsidiary focusing on treatment of urologic and gynecologic disorders says it is "currently seeking an initial round of financing." Funding would be used to support product development, completion of preclinical testing of Micro's Embolyx polymer as a urethral bulking agent for incontinence under a cross-licensing agreement, "and initiation of human clinical trials." Heading the new unit as president and CEO will be Thomas Berryman, Micro's current chief financial officer. Embolyx, which consists of a biocompatible polymer and contrast agent dissolved in a solvent carrier for injection into the body, is currently under development by Micro for neurointerventional applications ("The Gray Sheet" Nov. 24, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel